ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares - Gilde Healthcare

ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordi...

November 14, 2017

LEIDEN, The Netherlands (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the pricing of its previously announced underwritten public offering and concurrent registered direct offering of its ordinary shares at a price to the public of $3.25 per share.  All of the shares are being offered by ProQR.  In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions.  Gross proceeds from both offerings are expected to be approximately $20 million, assuming no exercise of the underwriters’ option to purchase additional shares in the public offering.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering. National Securities Corporation is acting as co-manager for the offering.

The pricing for the underwritten public offering was for a total of 4,969,805 ordinary shares for expected gross proceeds of $16.15 million.  The pricing for the concurrent registered direct offering was for a total of 1,427,692 ordinary shares for expected gross proceeds of $4.64 million. The offerings are expected to close on November 16, 2017, subject to customary closing conditions. In addition, closing of the registered direct offering is contingent upon ProQR completing the public offering. The registered direct offering was made without an underwriter or a placement agent. 

A shelf registration statement relating to the offered ordinary shares was filed with the Securities and Exchange Commission (SEC) on October 2, 2015, which was declared effective on October 19, 2015.  A preliminary prospectus supplement related to the underwritten public offering has been filed with the SEC and is available on the SEC’s website, located at www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to each offering may be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 4th Floor, New York, New York 10022, or by e-mail: placements@hcwco.com or by telephone: 646-975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the first commercial cases of the MISHA™ Knee System, an implantable shock absorber...
September 6, 2023

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

In 2014, Withings, a pioneer of the digital health movement, announced the world’s first hybrid watch. Today it furthers its leadership of the hybrid connected watch sector, unveiling the latest generation of its groundbreaking ScanWatch....
August 31, 2023

Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix

Big Health, the leading provider of non-drug digital treatments for mental health, has acquired Limbix, creators of the first, evidence-based digital therapeutic for teens and young adults with symptoms of depression. Since its founding in...
July 17, 2023